SCHEMBL19862662

SCHEMBL19862662

CCn1c(N2CCC(N)CC2)nc(Cl)cc1=O

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 10/20 0.53
SOS1 Q07889 2/20 0.41
HTR3E A5X5Y0 1/20 0.40
MEN1 O00255 1/20 0.40
HTR3B O95264 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
NFKB1 P19838 1/20 0.40
HTR3A P46098 1/20 0.40
KMT2A Q03164 1/20 0.40
HTR3D Q70Z44 1/20 0.40
HTR3C Q8WXA8 1/20 0.40
HRH4 Q9H3N8 1/20 0.36
DPP4 P27487 3/20 0.35
KCNH2 Q12809 2/20 0.35
SSTR2 P30874 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19666792 0.80 SMO (0.38) KDM1ATSHR
SCHEMBL17222691 0.71 KDM1A (1.00) KDM1ADPP4KCNH2
SCHEMBL24012951 0.70 POLB (0.46) MEN1CYP1A2CYP2D6TSHRNFKB1
SCHEMBL17222668 0.69 POLB (0.40) MEN1CYP1A2CYP2D6TSHRNFKB1
SCHEMBL19862684 0.66 POLB (0.38) MEN1CYP1A2CYP2D6TSHRNFKB1
SCHEMBL22193250 0.64 MAPT (0.42) HTR3EMEN1HTR3BCYP1A2CYP2D6
Hydrochloric Acid SCHEMBL11313733 0.63 MEN1 (0.59) HTR3EMEN1HTR3BCYP1A2CYP2D6
SCHEMBL17230733 0.63 POLB (0.35) MEN1CYP1A2CYP2D6TSHRNFKB1
Hydrochloric Acid SCHEMBL3280602 0.62 MEN1 (0.50) KDM1AHTR3EMEN1HTR3BCYP1A2
SCHEMBL14336833 0.60 CHRM2 (0.53) HTR3EMEN1HTR3BCYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3137169-B1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 CELGENE QUANTICEL RES INC (US) 2021-11-10 EP disclosed
WO-2018031658-A1 TREATMENT OF RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN'S LYMPHOMAS CELGENE CORPORATION (US) 2018-02-15 WO disclosed